Leveraging Lessons Learned from the COVID-19 Pandemic for HIV
Overview
Authors
Affiliations
The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.
Parvin N, Mandal T, Joo S Pharmaceutics. 2024; 16(11).
PMID: 39598489 PMC: 11597542. DOI: 10.3390/pharmaceutics16111366.
Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials.
Lezo Ramirez D, Koleske E, Ometoruwa O, Park Chang J, Kanwal U, Morreale N Front Public Health. 2024; 12:1411970.
PMID: 39131572 PMC: 11311253. DOI: 10.3389/fpubh.2024.1411970.